-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
recently, arterial network through foreign media information learned that medical device company Spectral MD announced the completion of $27 million in financing (not announced specific rounds). The investor is Biomedical Advanced Research and Development Authority (BARDA), a U.S. government agency.
Spectral MD plans to use this round of funding to develop DeepView, an AI-driven wound imaging system, primarily to diagnose burns and help improve their clinical efficacy. In addition, Spectral MD will conduct DeepView clinical trials in diagnosing diseases such as amputations, severe limb isemia (CLI) and diabetic foot ulcers.
Founded in 2009 and headquartered in Texas, Spectral MD is a medical device company in the clinical research phase. The company develops wound imaging systems based primarily on artificial intelligence to improve the treatment of burn patients. Spectral MD was one of the first startups to apply computer vision to medical diagnostics.
Spectral MD develops DeepView, a medical diagnostic device based on multispectral image technology. The device records the wavelength of light reflected by the substance and analyzes its chemical structure to identify pathological tissues that are difficult for the naked eye to judge. DeepView is a non-destructive detection device that combines deep learning algorithms and is currently used primarily to distinguish healthy tissue and pathological tissue in burn patients, helping surgeons improve treatment efficiency and reduce the risk of skin grafts.
In addition, DeepView can handle serious burns and mass casualties. For example, in accidents such as fires or radiation that can easily result in large numbers of casualties, thousands of patients with severe burns may also need skin grafts. DeepView's advanced diagnostic technology helps doctors quickly determine a patient's condition for timely treatment.
DeepView has been recognized by the FDA for breakthrough medical devices. Clinical trials showed that the device greatly improved the imaging speed of human burn tissue, and the diagnosis error rate was 5%, which is much lower than the misdiagnosis rate of manual diagnosis. (Arterial mesh)
